CTAG1B and McLeod neuroacanthocytosis syndrome: A phase II trial (NCT02609984, Table 2) compared the combination of CMB305 and atezolizumab (anti‐PD‐1) to atezolizumab alone in 89 patients with NY‐ESO‐1‐expressing synovial sarcoma or MLS.